In search of a cure for solid organ cancers
Make a donation
Become a sponsor
Car-T Mesothelin Research
Cure The Future are raising funds for Australian research as part of a Global Initiative into using Mesothelin CAR-T Cells to fight certain cancers.
Early clinical data from leading research centres around the World highlights the promise of Chimeric Antigen Receptor (CAR) T cells for the targeted treatment of cancers such as pancreatic cancer, muscle cancer, ovarian cancer, some breast cancers and asbestos-related lung cancer.
A collaboration of international researchers agree it is the best possible promise of a cure we have seen – so they have got together to do clinical trials of this treatment. Australia’s team, led by Professor John Rasko, Asutralia’s leading Cell & Molecular Therapies specialist, will leverage the existing cell manufacturing infrastructure and expertise at the Cell & Molecular Therapies department at Royal Prince Alfred Hospital.
International collaborators will work together to develop these anti-mesothelin CAR-T cells – and initiate Phase I clinical trials to treat each of these cancer conditions.
In Australia, our initial focus will be on the treatment of advanced pancreatic cancer. This treatment option will be a first for Australian patients – and cellular immunotherapy of the type proposed here may revolutionise outcomes for patients and their families living with many types of cancer.
Our “CAR-T mesothelin” cancer immunotherapy is potentially capable of targeting pancreatic, ovarian, synovial and mesothelioma (a subset of lung cancer caused by exposure to asbestos) and well as other lung cancer & breast cancer subsets.
Be part of this historical ground-breaking global project and help Cure The Future – for your family and for families like yours, all over the World.
With your help, we can cure the future
Cure The Future are raising funds for Australian research as part of a global initiative into using Mesothelin CAR-T Cells to fight certain cancers